Renal Recovery following Liposomal Amphotericin B-Induced Nephrotoxicity

Abstract EN

Background.

Acute kidney injury (AKI) is a common complication of treatment with liposomal amphotericin B (LAmB).

The trajectory of renal recovery after LAmB-associated AKI has not been well described, nor has effect of LAmB dose on recovery of renal function been explored.

Objective.

Characterize the pattern of renal recovery after incident AKI during LAmB and determine potential influencing factors.

Methods.

This retrospective cohort study analyzed patients who developed a ≥50% increase in serum creatinine while on LAmB.

Patients were followed up until complete renal recovery or death or for 30 days, whichever occurred first.

The primary outcome was complete renal recovery, defined as serum creatinine convalescence to within 10% of the patient’s pretreatment baseline.

Multivariable modeling was used to identify independent predictors of renal recovery.

Results.

Ninety-eight patients experienced nephrotoxicity during LAmB, 94% of which received doses <7 mg/kg/day.

Fifty-one patients at least partially recovered renal function and, of these, 32 exhibited complete recovery after a mean 9.8 ± 7.8 days.

No statistical relationship was found between LAmB dose at the time of AKI or cumulative exposure to LAmB and the likelihood of renal recovery.

Concomitant nephrotoxins, age, and pretreatment renal function did not modify this effect in multivariable analysis.

Conclusion and Relevance.

Our data suggests that LAmB dose did not impact the likelihood of renal recovery.

Additional investigation is needed to confirm these findings when aggressive dosing strategies are employe.

Additional research is also warranted to further characterize the course of recovery after LAmB-associated nephrotoxicity and comprehensive spectrum of renal outcomes.